Showing 2071-2080 of 5696 results for "".
- Apellis Pharmaceuticals’ APL-2 Receives FDA Fast Track Designation for the Treatment of Patients with GAhttps://modernod.com/news/apellis-pharmaceuticals-apl-2-receives-fast-track-designation-from-fda-for-the-treatment-of-patients-with-geographic-atrophy/2479993/Apellis Pharmaceuticals announced that the FDA has granted fast track designation to the company’s APL-2, a novel inhibitor of complement factor C3 as a next generation monotherapy, for the treatment of patients with geographic atrophy (GA). The FDA’s fast track program faci
- Aerie Pharmaceuticals Announces Early Notification of FDA Acceptance of NDA Submission for Roclatanhttps://modernod.com/news/aerie-pharmaceuticals-announces-early-notification-of-fda-acceptance-of-nda-submission-for-roclatan/2479999/Aerie Pharmaceuticals reported that it has received the “Day 74” notification from the FDA earlier than scheduled. The FDA has completed its initial 60-day review of the new drug application (NDA) for Roclatan (netarsudil/latanoprostnetarsudil ophthalmic solution) 0.02%/0.005% and the FDA has det
- Novartis Chairman Says Alcon Worth $20 Billion to $30 Billion: Finanz und Wirtschafthttps://modernod.com/news/novartis-chairman-says-alcon-worth-20-billion-30-billion-finanz-und-wirtschaft/2480052/The chairman of Swiss Novartis expects Alcon to be valued at between $20 billion and $30 billion when the ophthalmic devices unit is spun off to shareholders next year, he said in an interview with Finanz und Wirtschaft, according to a Reuters
- Neuro-Optometric Rehabilitation Association (NORA) Launches Redesigned Website; Accepts Award Nominationshttps://modernod.com/news/neuro-optometric-rehabilitation-association-nora-launches-redesigned-website-accepts-award-nominations/2480061/The Neuro-Optometric Rehabilitation Association, International (NORA) announced the launch of its redesigned website and new domain name, www.noravisionrehab.org, dedicated to educating patients, caregivers, and health care professionals about neurolog
- LayerBio Awarded $1.2 Million from NIH to Develop Sustained-Release Glaucoma Drughttps://modernod.com/news/layerbio-awarded-1-2-million-from-nih-to-develop-sustained-release-glaucoma-drug/2480164/Founded in 2013 as a spin-off from the lab of Dr. Paula Hammond at MIT, LayerBio is developing novel drug delivery products for ophthalmology, wound care, tendon repair and other unmet medical needs. The National Eye Institute at the National I
- Hoya Achieves CE Mark for 4-in-1 Multisert Preloaded Delivery System with Vivinex IOLhttps://modernod.com/news/hoya-achieves-ce-mark-for-4-in-1-multisert-preloaded-delivery-system-with-vivinex-iol/2480171/Hoya Surgical Optics has obtained European CE Mark for the Vivinex IOL with the new multiSert 4-in-1 preloaded delivery system. MultiSert offers cataract surgeons control in the palm of their hands as they now have the option of using either a two-handed screw or a one-handed technique while impl
- Novaliq to Present Scientific and Clinical Research During the 2018 ARVO Meeting in Honoluluhttps://modernod.com/news/novaliq-to-present-scientific-and-clinical-research-during-the-2018-arvo-meeting-in-honolulu/2480208/Novaliq announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) meeting in Honolulu, Hawaii (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With th
- Novartis Launches App to Collect Patient Data in Studies for Ophthalmic Diseaseshttps://modernod.com/news/novartis-launches-app-to-collect-patient-data-in-studies-for-ophthalmic-diseases/2480209/Novartis announced the launch of its FocalView app, an ophthalmic digital research platform that aims to allow researchers to track disease progression by collecting real-time, self-reported data directly from consenting patients. By adapting the design of clinical trials to suit the daily routin
- Oculis Begins Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Diseasehttps://modernod.com/news/oculis-begins-phase-2b-relief-trial-of-topical-anti-tnfa-licaminlimab-ocs-02-in-dry-eye-disease/2481998/Oculis announced 'First Patient First Visit' (FPFV) in its phase 2b RELIEF trial evaluating the potential of licaminlimab (also known as OCS-02), Oculis’ anti-TNFα biologic eye drop drug candidate for the treatment of dry eye disease (DED). The phase 2b REL
- Orbis Flying Eye Hospital Begins 2-Week Training Project to Improve Eye Care Across Rwandahttps://modernod.com/news/orbis-flying-eye-hospital-begins-two-week-training-project-to-improve-eye-care-across-rwanda/2482898/The Orbis Flying Eye Hospital landed in Kigali, Rwanda, on July 18, 2025, marking the beginning of a historic 2-week training project. It marks the first time this aircraft has visited Rwanda, where Orbis' teams of clinical staff and volunteer faculty will work alongside t